Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company is currently conducting Phase 2 MOMENTUM trial for obesity with topline data expected in 2026, positioning it in the highly competitive but lucrative GLP-1 weight loss market dominated by Novo Nordisk and Eli Lilly. With minimal revenue ($0.0M TTM), the company is entirely dependent on clinical trial success and capital markets access to fund operations through commercialization.
Altimmune operates a classic biotech development model: raise capital through equity offerings and grants, invest in clinical trials to demonstrate safety/efficacy, then either commercialize independently or partner/license assets to larger pharma companies. The company's value proposition centers on pemvidutide's differentiated profile versus existing GLP-1 therapies - claiming superior weight loss (mean 15.6% at 48 weeks in Phase 1b), weekly subcutaneous dosing, and potential liver benefits for MASH. Monetization depends entirely on successful Phase 2/3 trials, regulatory approval, and either building commercial infrastructure or securing partnership deals with 20-30% royalty rates typical in the sector. Current burn rate of approximately $100M annually means the company needs sustained capital access or partnership milestones.
Pemvidutide Phase 2 MOMENTUM trial data readouts - weight loss efficacy, safety profile, and liver biomarker improvements versus Wegovy/Zepbound benchmarks
Clinical trial enrollment milestones and timeline updates for obesity and MASH indications
Partnership announcements or licensing deals with major pharma (Novo Nordisk, Eli Lilly, Pfizer, Amgen) for commercialization rights
Equity financing announcements and cash runway extensions - critical given $100M+ annual burn and $72M cash position (estimated Q4 2025)
Competitive landscape developments in GLP-1 market - oral formulations, next-gen dual/triple agonists, pricing pressure from biosimilars
Clinical trial failure risk - Phase 2/3 obesity trials have 30-40% failure rates; pemvidutide must demonstrate non-inferior efficacy to Wegovy (15% weight loss) while proving differentiated safety/tolerability profile to justify market entry against entrenched competitors
Regulatory pathway uncertainty - FDA obesity drug approvals require cardiovascular outcomes trials (CVOTs) adding 3-5 years and $200-300M in costs; MASH indication has no approved therapies yet, creating regulatory precedent risk
Competitive obsolescence - rapid innovation in metabolic disease space with oral GLP-1s (Rybelsus), triple agonists (retatrutide), and gene therapies potentially rendering injectable weekly GLP-1/glucagon agonists outdated before commercialization
Manufacturing scale-up risk - transitioning from clinical to commercial GLP-1 production requires specialized facilities and supply chain (peptide synthesis, cold chain) with 18-24 month lead times
Dominant incumbents with massive resources - Novo Nordisk (Wegovy, $1.8B Q3 2025 sales) and Eli Lilly (Zepbound, $1.3B Q3 2025 sales) control 90%+ market share with established payer relationships, DTC marketing, and manufacturing scale that Altimmune cannot match independently
Crowded pipeline - 50+ GLP-1 programs in development including oral formulations (Pfizer danuglipron, Eli Lilly orforglipron) and next-gen molecules (Viking VK2735, Amgen AMG-133) with potentially superior profiles, compressing partnership valuations and commercial opportunity
Cash runway risk - estimated $72M cash (Q4 2025) against $100M+ annual burn implies 6-9 month runway without additional financing; requires dilutive equity raise in 2026 likely at depressed valuation given -31.2% 1-year stock performance
Equity dilution overhang - pre-revenue biotechs typically require 3-5 financing rounds before commercialization, each diluting existing shareholders 20-40%; current 0.4B market cap implies limited financing capacity without reverse split
Going concern risk if Phase 2 data disappoints - failed trial would eliminate partnership interest and close equity financing windows, forcing asset sales or wind-down
moderate - Clinical-stage biotechs show indirect GDP sensitivity through two channels: (1) capital markets access for financing, which tightens during recessions as risk appetite declines and biotech IPO/follow-on windows close, and (2) future commercial opportunity sizing, as obesity treatments require sustained out-of-pocket spending (insurance coverage remains limited) making demand somewhat discretionary. However, core clinical operations continue regardless of cycle, and the obesity market's secular growth trajectory (projected $100B+ by 2030) provides insulation from short-term economic fluctuations.
High sensitivity through multiple mechanisms. Rising rates compress biotech valuations by increasing discount rates applied to distant cash flows (pemvidutide revenue unlikely before 2028-2030), making the -$100M annual cash burn more expensive in present value terms. Higher rates also reduce speculative capital flowing into pre-revenue biotechs, evidenced by sector-wide valuation compression in 2022-2023 when Fed raised rates 525bps. Additionally, rising rates increase opportunity cost of holding cash-burning equities versus risk-free Treasuries. The 17.18x current ratio provides liquidity buffer, but sustained high rates force earlier dilutive financings.
Minimal direct credit exposure given negligible debt (0.09 D/E ratio). However, credit market conditions indirectly impact through: (1) biotech-focused venture debt availability for non-dilutive financing, (2) acquisition appetite from strategic buyers (pharma M&A activity correlates with credit availability), and (3) SPAC/IPO market functionality for sector liquidity. Widening high-yield spreads signal risk-off sentiment that typically hammers clinical-stage names regardless of individual credit quality.
High-risk growth and momentum investors seeking asymmetric biotech binary events. Attracts speculative capital focused on Phase 2 data catalysts with 3-10x upside if trials succeed, accepting 70-90% downside if they fail. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail traders chasing GLP-1 thematic exposure at lower entry price than Novo/Lilly. Not suitable for value or income investors given negative cash flows and no dividend. The 25.3% 6-month return despite -31.2% 1-year performance indicates momentum-driven trading around clinical milestones.
High volatility - clinical-stage biotechs typically exhibit 60-100% annualized volatility with 20-50% single-day moves on trial data releases. The -4.1% 3-month return masking 25.3% 6-month gain demonstrates whipsaw price action. Options market likely prices 80-100% implied volatility around data catalyst dates. Beta to broader market likely 1.5-2.0x, but idiosyncratic clinical risk dominates systematic risk.